|
CONSUMER NEWS RECALLS COMPLAINT FORM SCAM ALERTS |
| Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish | |
|
|
![]() |
British Heart Patients Told to Stop Taking Cox-2 Drugs |
|||||
|
December 22, 2004
"Patients treated with any COX-2 inhibitor who have established ischaemic heart disease or cerebrovascular disease should be switched to alternative (non-COX-2 selective) treatments as soon as is convenient," the agency said. The letter also reminds doctors that all nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors, should be prescribed at the lowest effective dose for the shortest duration necessary. Other popular NSAIDs include naproxen, ibuprofen and aspirin. "We are aware that new data from a clinical trial in the United States has indicated an increased cardiovascular risk (including heart attack and stroke) following treatment with celecoxib (Celebrex)," the agency said in a statement on its Web site. "We have today issued a letter to healthcare professionals giving interim advice on prescribing of all COX-2 inhibitors, in light of emerging evidence, and have produced a question and answer document. Definitive advice will be issued, once further information is available and has been evaluated," it said. "Patients receiving treatment with celecoxib (Celebrex) or other selective COX-2 inhibitors should not be alarmed and should make a non-urgent appointment with their GP to have their treatment reviewed," MHRA's statement concluded. "For all patients, alternative treatments should be considered in light of an individual assessment of risks and benefits of COX-2 inhibitors, in particular cardiovascular, gastrointestinal and other risk factors," said Professor Gordon Duff, Chairman of the Committee on Safety of Medicines, the author of the letter. MHRA noted that a recent letter to healthcare professionals from Pfizer, which highlighted the supposed cardiovascular safety of Celebrex, was "not authorised by the MHRA". The latest Celebrex study, conducted by the US National Cancer Institute, found that the risk of heart attacks and strokes was 2.5 times higher in patients taking the 400-mg dose of the drug and 3.4 times higher with the 800-mg dose. Report Your Experience
|
|||||
Back to the top | |
||||||
|
Home |
Rogues Gallery |
Good Guys |
Complaint Form |
News |
Recalls |
Search |
Site Map |
FAQ |
|
Advertisement
Terms of Use Your use of this site constitutes acceptance of the Terms of Use
Copyright © 2003-2008 ConsumerAffairs.com Inc. All Rights Reserved. |
|